ELDN · XBRL financial data

Eledon Pharmaceuticals financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ELDN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	6,131	23,735	27,080	30,312	51,964	66,267
General and administrative	10,052	13,132	12,700	12,688	18,613	16,984
Total operating expenses	18,465	36,867	88,428	43,000	70,577	83,251
Operating income (loss)	(18,465)	(36,867)	(88,428)	(43,000)	—	—
Other income (expense)	79	7	462	2,674	3,924	4,220
Income tax expense (benefit)	(404)	(2,354)	0	0	431	35
Net income (loss)	(22,811)	(34,506)	(87,966)	(116,537)	(36,184)	(45,617)
Earnings per share, basic USD per share	—	(2.33)	(6.16)	(4.73)	(0.75)	(0.52)
Earnings per share, diluted USD per share	—	(2.33)	(6.16)	(4.73)	(0.75)	(0.52)
Weighted average shares, basic thousands of shares	—	14,820	14,285	24,619	48,544	81,836
Weighted average shares, diluted thousands of shares	—	14,820	14,285	24,619	48,544	81,836

Fiscal years (ELDN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	114,195	84,833	56,409	4,612	20,549	22,808
Short-term investments	—	—	0	46,490	119,629	110,528
Prepaid and other current assets	1,435	3,513	3,109	5,027	3,552	2,352
Total current assets	115,630	88,346	59,518	56,129	143,730	135,688
Right-of-use asset	138	768	739	365	926	613
Goodwill	48,648	48,648	0	0	—	—
Total assets	197,185	170,548	92,793	89,066	177,405	169,009
Accounts payable	1,366	1,813	2,200	967	5,833	3,627
Total current liabilities	2,483	4,401	6,475	3,895	11,577	18,344
Lease liability, non-current	—	400	383	0	640	283
Total liabilities	6,589	6,553	8,610	81,858	59,265	32,230
Accumulated deficit	(80,393)	(114,899)	(202,865)	(319,402)	(355,586)	(401,203)
Total stockholders' equity	190,596	163,995	84,183	7,208	62,446	81,085
Total liabilities and equity	197,185	170,548	92,793	89,066	177,405	169,009
Common shares outstanding (cover page) thousands of shares	14,307	14,307	13,777	24,813	59,882	75,852

Fiscal years (ELDN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(22,811)	(34,506)	(87,966)	(116,537)	(36,184)	(45,617)
Net cash from operating activities	(15,212)	(28,913)	(28,424)	(39,527)	(47,271)	(62,341)
Net cash from investing activities	11,035	—	—	(45,287)	(70,314)	10,793
Proceeds from issuing common stock	9,000	—	—	—	—	—
Net cash from financing activities	109,581	(449)	—	33,017	133,522	53,807
Net change in cash	105,404	(29,362)	(28,424)	(51,797)	15,937	2,259

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Eledon Pharmaceuticals	6,803	not reported	(22,677)*	81.3M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Puma Biotechnology	36,537	56,502	1,624*	51.6M	—	Q2 FY26 10-QJun 30, 2026
Neurogene	112,485	not reported	(23,761)*	20.0M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Voyager Therapeutics	35,769	3,165	(25,842)*	61.6M	4.5 quarters	Q2 FY26 10-QJun 30, 2026
Aclaris Therapeutics	19,167	1,629	(19,847)*	147.2M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Vistagen Therapeutics	16,991	not reported	(14,707)	44.4M	2.2 quarters	Q1 FY27 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.